Life just got more difficult for those fighting antibiotic-resistant superbugs. Researchers at McGill University have ...

By fusing enzyme fragments to antibodies, researchers from the Institute of Science Tokyo, in Japan, developed an innovative ...

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical ...

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme Pin1, a protein that is overexpressed in many tumors ...

Last year, researchers at the University of California, Riverside, developed a novel "molecular crowbar" strategy to degrade ...

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related ...

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulati ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...